Summary of Hyperfine Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $3.9 million for Q2 2026, up 45% year-over-year; total revenue for the first half of 2026 reached $7.8 million, a 62% increase from the prior year.

Unit Sales: Sold 12 systems in Q2 2026, a 50% increase from 8 units in Q2 2025; total units sold in the first half were 22, up from 14 year-over-year.

Gross Profit: $2 million in Q2 2026, with a gross margin of 50.7%, marking the fourth consecutive quarter above 50%.

Net Loss: $9.3 million for Q2 2026, compared to a loss of $9.2 million in Q2 2025; net loss per share improved to $0.09 from $0.12.

Cash Burn: Net cash burn was $7.9 million in Q2 2026, slightly improved from $8.1 million in Q2 2025; total cash burn for the first half was $16.6 million, down from $18.2 million.

Cash Position: As of June 30, 2026, cash and cash equivalents totaled $43.5 million, bolstered by $10.6 million raised through an ATM program.

2Strategic Updates and Business Highlights

Product Launch: Continued success of the next-generation Swoop system (Model 2) with increased adoption across hospitals, neurology offices, and international markets.

Market Expansion: Significant progress in the hospital market with broader utility beyond critical care, including emergency departments and clinics.

Neurology Office Growth: The office market is developing as a distinct growth vertical, with high scan volumes reported and interest in additional applications like dementia screening.

International Sales: Initial sales in Europe and India following regulatory approvals, with plans for further rollout in the second half of 2026.

Software Development: Upcoming software enhancements aimed at improving clinical utility and user experience, with a focus on expanding labeling to include contrast agents.

3Forward Guidance and Outlook

Revenue Guidance: Full-year 2026 revenue expected to be between $20 million and $22 million, representing approximately 55% growth at the midpoint.

Gross Margin: Anticipated to remain between 50% and 55% for the year.

Cash Burn: Expected to total between $26 million and $28 million for 2026, indicating a 10% year-over-year decline.

Cash Runway: Projected to extend into 2028, supported by a strengthened balance sheet and disciplined spending.

4Challenges and Points of Concern

Net Loss: While the net loss per share improved, the overall net loss remains substantial, indicating ongoing financial challenges.

Market Competition: The need to maintain competitive advantages in a rapidly evolving market with potential pressures from other imaging technologies.

Execution Risks: Dependence on successful execution of growth strategies in hospitals, offices, and international markets, which could be influenced by external factors like regulatory changes and economic conditions.

5Notable Q&A Insights

Guidance Breakdown: Management clarified that the second-half revenue guidance includes repeat placements in existing Integrated Delivery Networks (IDNs) and new site placements, with identifiable catalysts driving growth.

Office Market Strategy: Discussion on the potential for offering both Model 1 and Model 2 systems, with a focus on larger practices likely to adopt Model 2 due to higher volume and economic benefits from contrast MRI capabilities.

Growth Potential: Management expressed confidence in the office market becoming a significant contributor to growth, supported by increased utilization and planned product enhancements. Overall, Hyperfine demonstrated strong financial performance in Q2 2026, with significant year-over-year growth and strategic advancements across multiple business verticals, while also acknowledging ongoing challenges and the need for continued execution on growth initiatives.